CureVac’s Covid-19 vaccine was 48 percent effective in the final analysis of the company’s pivotal mass trial, only marginally better than the 47 percent reported after an initial read-out two weeks earlier.
Intellia Therapeutics and Regeneron Pharmaceuticals shook the biotech and CRISPR world on June 26, announcing positive early data from the first-ever patients to have their DNA edited with an in vivo CRISPR/Cas9 therapy delivered systemically.
In this webinar hear from “both sides of the house” – first from an innovative information technology leader and then a senior scientist who uses the solutions provided by IT. Learn how MOMA Therapeutics’ innovative lead discovery solution can be applied to the needs of biotechnology discovery workflows.
Hong Kong-based Insilico Medicine closed on a Series C financing round worth $255 million.
A sense of urgency, powerful science, relentless ingenuity, hope and trust drove the development of Pfizer and BioNTech’s mRNA vaccine during the height of the Covid-19 pandemic. As the crisis appears to lessen, Pfizer is preparing for the next pandemic.
Last year challenged biotech and pharma companies to explore what is possible. When several companies can develop COVID-19 vaccines at a record pace, it proves that the industry is capable of massive feats.
CEO Usama Malik is leading an exciting period of growth for Fore Biotherapeutics as the company evolves as a leader in precision oncology with its unique business model and ability to deliver the right therapies to currently underserved patients.
Venture capitalist Chamath Palihapitiya is raising $800 million to finance four more special purpose acquisition companies (SPAC) that will be focused on taking biotech companies public.
2021 is shaping up to be another banner year for biotech companies. According to BioSpace, funds appear to be in near-endless supply as companies advance next-gen technologies and therapeutics for the health of all. BioSpace reviews a few raking in cash for their programs.
BioSpace takes a look at Series A financing rounds for several biotech companies: San Francisco-based Esker Therapeutics; England’s Mogrify Limited; Duke University spinout Isolere Bio; and Sunnyvale, California-based BridGene Biosciences.
